Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Weekly vs Every 3 Weeks in Metastatic Breast Cancer
NCT00008411Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 1999
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Tumor Response Rate. Started Dec 1999; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00008411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00008411.